title: Cerebral β-amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage.
abstract: Cerebral amyloid angiopathy (CAA) may be an important predisposing factor for the hemorrhagic complications of recombinant tissue-type plasminogen activator (rt-PA) therapy. We studied patients treated within 3 hours of onset of ischemic stroke with rt-PA using positron emission tomography to compare Pittsburgh compound B (PiB) (a cerebral β-amyloid ligand) retention in those with and without parenchymal hemorrhage (PH) and normal controls. Neocortical PiB retention was higher among patients with PH compared with patients without PH and normal controls, suggesting underlying CAA as a predisposing factor for rt-PA-related hemorrhage. This finding may provide an impetus for the development of a more practical rapid pretreatment screening technique.
authors.affiliation: National Stroke Research Institute, Austin Health, University of Melbourne, Heidelberg Heights, Australia.
authors.forename: John V
authors.initials: JV
authors.lastname: Ly
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Rowe
authors.forename: Victor L
authors.initials: VL
authors.lastname: Villemagne
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Zavala
authors.forename: Henry
authors.initials: H
authors.lastname: Ma
authors.forename: Graeme
authors.initials: G
authors.lastname: O'Keefe
authors.forename: Sylvia J
authors.initials: SJ
authors.lastname: Gong
authors.forename: Rico
authors.initials: R
authors.lastname: Gunawan
authors.forename: Leonid
authors.initials: L
authors.lastname: Churilov
authors.forename: Tim
authors.initials: T
authors.lastname: Saunder
authors.forename: Uwe
authors.initials: U
authors.lastname: Ackerman
authors.forename: Henri
authors.initials: H
authors.lastname: Tochon-Danguy
authors.forename: Geoffrey A
authors.initials: GA
authors.lastname: Donnan
mesh_terms: D000368:Aged; D000814:Aniline Compounds; D052160:Benzothiazoles; D016657:Cerebral Amyloid Angiopathy / Q000000981:diagnostic imaging* / Q000209:etiology; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced* / Q000150:complications*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods; D012372:ROC Curve; D012189:Retrospective Studies; D020521:Stroke / Q000188:drug therapy; D013844:Thiazoles; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000814:Aniline Compounds; D052160:Benzothiazoles; D005343:Fibrinolytic Agents; D013844:Thiazoles; D010959:Tissue Plasminogen Activator